ZYZhibin Yu

Zhibin Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhibin Yu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Visualizing Phase Evolution of Co2C for Efficient Fischer–Tropsch to Olefins

    by Xiaoling Hong, Qiao Zhao, Yanping Chen, Zhibin Yu, Mengzhen Zhou, Yan Chen, Wenhao Luo, Chang Wang, Na Ta, Haitao Li, et al.

    Cobalt carbide (Co2C) possesses high catalytic efficiency Fischer–Tropsch synthesis (FTS), while the products selectivity appears sensitive to crystallography geometry. Since the Anderson–Schulz–Flory (ASF) distribution in FTS is broken through fabricating facetted Co2C nanocrystals, yet the underlying mechanism of Co2C crystallization remains unclarified suffering from sophisticated catalyst composition involving promoter agents. Herein, the synthesis of high‐purity single‐crystal nanoprisms (Co2C‐p) for highly efficient FTS is reported to lower olefins. Through comprehensive microstructure analysis, e.g., high‐resolution TEM, in situ TEM and electron diffraction, as well as finite element simulation of gas flow field, for the first time the full roadmap of forming catalytic active cobalt carbides is disclosed, starting from reduction of Co3O4 precursor to CoO intermediate, then carburization into Co2C‐s and subsequent ripening growth into Co2C‐p. This gas‐induced engineering of crystal phase provides a new synthesis strategy, with many new possibilities for precise design of metal‐based catalyst for diverse catalytic applications.


  • Open Access

    Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine

    by Changrui Lu, Yuntao Zhang, Xiaohu Liu, Fujun Hou, Rujie Cai, Zhibin Yu, Fei Liu, Guohuan Yang, Jun Ding, Jiang Xu, et al.

    The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage. This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV). The ZSVG-02-O induces neutralizing antibodies that effectively cross-react with Omicron subvariants following an order of BA.1>BA.2>BA.4/5. In naïve animals, ZSVG-02 or ZSVG-02-O induce humoral responses skewed to the vaccine’s targeting strains, but cellular immune responses cross-react to all variants of concern (VOCs) tested. Following heterologous prime-boost regimes, animals present comparable neutralizing antibody levels and superior protection across all VOCs. Single-boost only generated ancestral and omicron dual-responsive antibodies, probably by “recall” and “reshape” the prime immunity. New Omicron-specific antibody populations, however, appeared only following the second boost with ZSVG-02-O. Overall, our results support a heterologous boost with ZSVG-02-O, providing the best protection against current VOCs in inactivated virus vaccine– primed populations.